Currently, two anti-HER2 agents, including humanized monoclonal antibody trastuzumab [7, 8] and the small-molecule tyrosine kinase inhibitor lapatinib [9], have been approved for use in the HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.